Investors

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Analysts following Egetis

 

Bryan, Garnier & Co: Oscar Haffen Lamm

Rx Securities: Joseph Hedden

Carnegie: Arvid Necander

Pareto Securities: Chien-Hsun Lee

ABG Sundal Collier: Alexander Krämer

Redeye: Fredrik Thor

 

 

 

 

 

Calendar and upcoming reports

November 26, 2024
DNB Nordic Healthcare Conference (Oslo)

December 3, 2024
Redeye Technology & Life Science Day (Stockholm & online)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]